Riociguat Impurity 11
WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com
Product Number: R018011
English Name: Riociguat Impurity 11
English Alias: 6-amino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-7-methyl-7H-purin-8(9H)-one
CAS Number: 1361569-18-7
Molecular Formula: C₁₉H₁₅FN₈O
Molecular Weight: 390.37
As Impurity 11 of Riociguat, this compound has the following advantages:
Well-defined with distinct polyheterocyclic features: Contains purine ring (6-amino, 8-keto, 7-methyl substituted), pyrazolo[3,4-b]pyridine ring, and 2-fluorobenzyl side chain. Unlike riociguat (soluble guanylate cyclase activator with pyrimidine ring), its keto group polarity, fluorine electronegativity, and polyheterocyclic conjugation create significant differences, enabling precise differentiation via HPLC/SFC as a specific marker;
High stability and traceability: Rigid polyheterocyclic (purine, pyrazolopyridine) structures and stability of amide bonds ensure neutral-condition stability. As a byproduct from incomplete purine ring oxidation or cyclization in riociguat synthesis, it directly reflects heterocyclic construction selectivity, improving process tracing accuracy;
High detection sensitivity: Polyheterocyclic conjugation shows strong UV absorption (250-290nm), combined with m/z 391 [M+H]⁺ enabling ppb-level analysis via LC-MS, compatible with soluble guanylate cyclase activator heterocyclic impurity systems.
Pharmaceutical quality control: Used as an impurity reference standard to quantify Riociguat Impurity 11 in APIs, ensuring residual purine-derived impurities meet quality standards;
Synthesis optimization: Optimizing heterocyclic construction conditions (oxidant selection) by monitoring impurity levels to enhance target pyrimidine ring specificity and reduce purine byproducts;
Intermediate purity assessment: Evaluating purity of key heterocyclic intermediates in riociguat synthesis to support subsequent side chain modification.
Riociguat is a soluble guanylate cyclase activator containing pyrazolo[3,4-b]pyridine and pyrimidine rings, synthesized via multi-step heterocyclic construction and side chain introduction. Purine ring isomerization or oxidation (instead of target pyrimidine formation) may generate 6-amino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-7-methyl-7H-purin-8(9H)-one derivatives like Riociguat Impurity 11. Due to structural differences between purine and pyrimidine affecting target binding, its residues impact riociguat efficacy and safety, requiring strict control.
Current research focuses on:
Analytical method validation: Developing HPLC assays with C18 columns for separation, achieving 0.1 ppb detection limits;
Cyclization mechanism: Studying impurity formation kinetics under varying cyclization reagents to clarify purine-pyrimidine isomerization pathways;
Control strategies: Using selective cyclization catalysts to keep impurity levels below 0.1% and enhance API purity;
Structural confirmation: Using ¹H/¹³C/¹⁹F-NMR to verify purine structure and substitution positions, distinguishing from riociguat for authoritative identification.
We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!
WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com
China
